Idenix files lawsuits in Europe, charging Gilead infringed on its patent by marketing hep C drug

This is a summary. To read the whole story subscribe to

Cambridge drug developer Idenix Pharmaceuticals Inc. has filed lawsuits in Europe charging that biotechnology giant Gilead Sciences Inc. infringed on an Idenix patent when it marketed a popular new hepatitis C treatment in England, France and Germany.

The suits escalate a three-month-old legal battle between Gilead and Idenix over the drug, called Sovaldi. Idenix — in which a Boston hedge fund has taken a growing position — says it has exclusive rights to intellectual property for sofosbuvir, the compound on which Sovaldi is based. The company lodged similar complaints against Gilead in California in December.

Idenix has not specified how much it is seeking in damages in its suits.

Full story for subscribers.

Get the full story with unlimited access to

Just 99 cents for four weeks.